IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO)
INR 60.95
(1.96%)
INR 60.95
(1.96%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.58 Billion INR | -24.49% |
| 2022 | 6.24 Billion INR | 9.32% |
| 2021 | 5.71 Billion INR | -30.45% |
| 2020 | 8.21 Billion INR | 5.54% |
| 2019 | 7.78 Billion INR | 32.44% |
| 2018 | 5.88 Billion INR | 134.65% |
| 2017 | 2.5 Billion INR | 17.68% |
| 2016 | 2.12 Billion INR | 33.21% |
| 2015 | 1.59 Billion INR | 51.54% |
| 2014 | 1.05 Billion INR | -45.5% |
| 2013 | 1.93 Billion INR | 6.63% |
| 2012 | 1.81 Billion INR | 6.33% |
| 2011 | 1.7 Billion INR | 15.52% |
| 2010 | 1.47 Billion INR | 118.12% |
| 2009 | 677.57 Million INR | 25.24% |
| 2008 | 541.03 Million INR | -10.25% |
| 2007 | 602.82 Million INR | 94.47% |
| 2006 | 309.99 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 961.4 Million INR | -16.63% |
| 2023 FY | 4.71 Billion INR | -24.49% |
| 2023 Q4 | 1.15 Billion INR | -29.87% |
| 2023 Q3 | 1.64 Billion INR | -14.26% |
| 2023 Q2 | 1.91 Billion INR | -3.25% |
| 2023 Q1 | 1.98 Billion INR | 20.5% |
| 2022 Q4 | 1.64 Billion INR | 8.67% |
| 2022 Q2 | 1.38 Billion INR | -18.66% |
| 2022 Q1 | 1.7 Billion INR | 67.17% |
| 2022 FY | 6.24 Billion INR | 9.32% |
| 2022 Q3 | 1.51 Billion INR | 9.17% |
| 2021 Q1 | 1.83 Billion INR | 30.54% |
| 2021 Q3 | 1.54 Billion INR | 16.6% |
| 2021 FY | 5.71 Billion INR | -30.45% |
| 2021 Q2 | 1.32 Billion INR | -27.94% |
| 2021 Q4 | 1.01 Billion INR | -33.84% |
| 2020 Q1 | 2.11 Billion INR | 42.77% |
| 2020 Q4 | 1.4 Billion INR | -38.0% |
| 2020 Q2 | 2.42 Billion INR | 14.66% |
| 2020 FY | 8.21 Billion INR | 5.54% |
| 2020 Q3 | 2.26 Billion INR | -6.7% |
| 2019 Q3 | 2.21 Billion INR | 12.92% |
| 2019 Q1 | 2.11 Billion INR | 29.02% |
| 2019 FY | 7.78 Billion INR | 32.44% |
| 2019 Q4 | 1.48 Billion INR | -33.14% |
| 2019 Q2 | 1.96 Billion INR | -7.26% |
| 2018 Q3 | 2 Billion INR | 49.72% |
| 2018 Q2 | 1.34 Billion INR | 50.47% |
| 2018 Q1 | 890.8 Million INR | 15.48% |
| 2018 FY | 5.88 Billion INR | 134.65% |
| 2018 Q4 | 1.64 Billion INR | -18.14% |
| 2017 Q3 | 774.8 Million INR | 12.32% |
| 2017 FY | 2.5 Billion INR | 17.68% |
| 2017 Q4 | 771.4 Million INR | -0.44% |
| 2017 Q1 | 644.2 Million INR | 8.6% |
| 2017 Q2 | 689.8 Million INR | 7.08% |
| 2016 FY | 2.12 Billion INR | 33.21% |
| 2016 Q4 | 593.2 Million INR | 0.36% |
| 2016 Q3 | 591.1 Million INR | 2.66% |
| 2016 Q2 | 575.8 Million INR | 4.24% |
| 2016 Q1 | 552.4 Million INR | 6.73% |
| 2015 Q2 | 374.8 Million INR | 17.21% |
| 2015 Q4 | 517.54 Million INR | 13.47% |
| 2015 FY | 1.59 Billion INR | 51.54% |
| 2015 Q1 | 319.76 Million INR | 119.45% |
| 2015 Q3 | 456.1 Million INR | 21.69% |
| 2014 FY | 1.05 Billion INR | -45.5% |
| 2014 Q4 | 145.71 Million INR | 0.15% |
| 2014 Q3 | 145.49 Million INR | -51.36% |
| 2014 Q2 | 299.15 Million INR | -35.61% |
| 2014 Q1 | 464.61 Million INR | 3.99% |
| 2013 Q4 | 446.79 Million INR | -9.03% |
| 2013 FY | 1.93 Billion INR | 6.63% |
| 2013 Q1 | 459.62 Million INR | 0.08% |
| 2013 Q2 | 528.83 Million INR | 15.06% |
| 2013 Q3 | 491.12 Million INR | -7.13% |
| 2012 Q2 | 446.31 Million INR | -2.37% |
| 2012 Q3 | 456.88 Million INR | 2.37% |
| 2012 Q4 | 459.26 Million INR | 0.52% |
| 2012 FY | 1.81 Billion INR | 6.33% |
| 2012 Q1 | 457.13 Million INR | 0.0% |
| 2011 FY | 1.7 Billion INR | 15.52% |
| 2010 FY | 1.47 Billion INR | 118.12% |
| 2009 FY | 677.57 Million INR | 25.24% |
| 2008 FY | 541.03 Million INR | -10.25% |
| 2007 FY | 602.82 Million INR | 94.47% |
| 2006 FY | 309.99 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 82.895% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 97.039% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 63.156% |
| Granules India Limited | 16.79 Billion INR | 72.732% |
| Indoco Remedies Limited | 6.04 Billion INR | 24.176% |
| Achyut Healthcare Limited | 4.86 Million INR | -94135.754% |
| Ajanta Pharma Limited | 21.06 Billion INR | 78.253% |
| Alkem Laboratories Limited | 52.29 Billion INR | 91.241% |
| Alpa Laboratories Limited | 188.89 Million INR | -2325.051% |
| Brooks Laboratories Limited | 65.62 Million INR | -6880.799% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 26.386% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -211.237% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -23.958% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 97.2% |
| Eris Lifesciences Limited | 10.42 Billion INR | 56.067% |
| FDC Limited | 8.33 Billion INR | 45.04% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 93.394% |
| Gufic Biosciences Limited | 4.16 Billion INR | -9.912% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 26.049% |
| Ipca Laboratories Limited | 29.8 Billion INR | 84.633% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -601.941% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -2276.834% |
| Lasa Supergenerics Limited | 121.02 Million INR | -3684.847% |
| Laurus Labs Limited | 24.62 Billion INR | 81.394% |
| Lupin Limited | 123.71 Billion INR | 96.297% |
| Mankind Pharma Limited | 44.52 Billion INR | 89.711% |
| Medicamen Biotech Limited | 495.49 Million INR | -824.49% |
| Medico Remedies Limited | 262.14 Million INR | -1647.437% |
| Megasoft Limited | 342.07 Million INR | -1239.137% |
| NATCO Pharma Limited | 25.73 Billion INR | 82.201% |
| Piramal Pharma Limited | 24.47 Billion INR | 81.281% |
| RPG Life Sciences Limited | 2.48 Billion INR | -84.487% |
| Sigachi Industries Limited | 2 Billion INR | -128.779% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 98.228% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -11.096% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -386.079% |
| Unichem Laboratories Limited | 4.86 Billion INR | 5.84% |
| Wanbury Limited | 1.73 Billion INR | -164.688% |
| Windlas Biotech Limited | 1.33 Billion INR | -242.157% |
| ZIM Laboratories Limited | 1.26 Billion INR | -261.579% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 96.342% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 860.417% |
| Divi's Laboratories Limited | 32.44 Billion INR | 85.879% |
| Hester Biosciences Limited | 1.27 Billion INR | -259.659% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 20.767% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -194.295% |
| Bal Pharma Limited | 770.19 Million INR | -494.758% |
| Strides Pharma Science Limited | 14.38 Billion INR | 68.163% |
| Venus Remedies Limited | 2.18 Billion INR | -109.88% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 21.445% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -54.129% |
| Shilpa Medicare Limited | 3.54 Billion INR | -29.151% |
| Aarti Drugs Limited | 8.31 Billion INR | 44.917% |
| Suven Life Sciences Limited | -200.79 Million INR | 2381.309% |
| Ind-Swift Limited | 2.17 Billion INR | -110.851% |
| Valiant Laboratories Limited | -60.66 Million INR | 7651.101% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 79.82% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -431.909% |
| Themis Medicare Limited | 1.5 Billion INR | -204.594% |
| Hikal Limited | 3.14 Billion INR | -45.742% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 90.203% |
| Sequent Scientific Limited | 2.97 Billion INR | -53.784% |
| Novartis India Limited | 1.32 Billion INR | -245.226% |
| Wockhardt Limited | 16.24 Billion INR | 71.793% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 76.68% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -31319.028% |
| Neuland Laboratories Limited | 8.24 Billion INR | 44.461% |
| Morepen Laboratories Limited | 6.16 Billion INR | 25.652% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -638.271% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -551.047% |